Literature DB >> 6811394

Valproate-induced hepatic injury: analyses of 23 fatal cases.

H J Zimmerman, K G Ishak.   

Abstract

Analyses of 23 fatal instances of hepatic injury in patients taking valproic acid reveals that all but three were less than 20 years old, and all but four had been taking the drugs for more than 1 month. Convulsions, facial edema, lassitude, and vomiting were prominent clinical features. Hypoglycemia was recorded in six patients. Rash and eosinophilia were not seen. Values for transaminases were modestly elevated in most patients. Most levels of SGOT were below 500 IU, and SGPT levels were below 200 IU. Livers showed microvesicular steatosis in most patients, usually accompanies by necrosis. Four patients had cirrhosis. Overt valproic acid-induced hepatic injury appears to be rare and hence, by definition, idiosyncratic. That it may be an idiosyncratic exaggeration of a much more frequent phenomenon is suggested by the higher incidence of seemingly trivial injury. The idiosyncrasy appears to be metabolic rather than immunologic, and the available information leads to the plausible hypothesis that a metabolite is responsible for the microvesicular steatosis seen in most fatal cases. The steatosis resembles that of Reye's syndrome and Jamaican vomiting sickness, and there is reason to believe that the metabolite responsible for the steatosis resembles the agent responsible for Jamaican vomiting sickness. A different metabolite is presumably responsible for the necrosis seen in many of the cases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811394     DOI: 10.1002/hep.1840020513

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  52 in total

1.  Serum free carnitine levels during valproic acid therapy.

Authors:  S Tütüncüoglu; H Tekgül; E Levent; A Hüseyinov
Journal:  Indian J Pediatr       Date:  1997 Jul-Aug       Impact factor: 1.967

Review 2.  Anticonvulsants and breast feeding: a critical review.

Authors:  B Bar-Oz; I Nulman; G Koren; S Ito
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

Review 3.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

4.  Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.

Authors:  M Bialer; S Hadad; B Kadry; A Abdul-Hai; A Haj-Yehia; J Sterling; Y Herzig; B Yagen
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 5.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

6.  The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.

Authors:  T Kondo; K Otani; T Hirano; S Kaneko; Y Fukushima
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

7.  Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report.

Authors:  Leila Mnif; Rim Sellami; Jawaher Masmoudi
Journal:  Psychopharmacol Bull       Date:  2016-08-15

8.  Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate.

Authors:  N Bach; S N Thung; F Schaffner; H Tobias
Journal:  Dig Dis Sci       Date:  1989-08       Impact factor: 3.199

9.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 10.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.